A review of potential novel glaucoma therapeutic options independent of intraocular pressure

Wesam Shamseldin Shalaby, Osama M. Ahmed, Michael Waisbourd, L. Jay Katz*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Glaucoma, a progressive optic neuropathy characterized by retinal ganglion cell degeneration and visual field loss, is the leading cause of irreversible blindness worldwide. Intraocular pressure (IOP) is presently the only modifiable risk factor demonstrated to slow or halt disease progression; however, glaucomatous damage persists in almost 50% of patients despite significant IOP reduction. Many studies have investigated the non-IOP-related risk factors that contribute to glaucoma progression as well as interventions that can prevent or delay glaucomatous neurodegeneration and preserve vision throughout life, independently of IOP. A vast number of experimental studies have reported effective neuroprotection in glaucoma, and clinical studies are ongoing attempting to provide strong evidence of effectiveness of these interventions. We look into the current understanding of the pathophysiology of glaucoma and explore the recent advances in non‐IOP related strategies for neuroprotection and neuroregeneration in glaucoma.

Original languageEnglish
Pages (from-to)1062-1080
Number of pages19
JournalSurvey of Ophthalmology
Issue number4
StatePublished - 1 Jul 2022


  • Gene therapy
  • Glaucoma
  • Intracranial pressure
  • Intraocular pressure
  • Neuroprotection
  • Ocular blood flow
  • Oxidative stress
  • Retinal ganglion cells
  • Stem cell therapy


Dive into the research topics of 'A review of potential novel glaucoma therapeutic options independent of intraocular pressure'. Together they form a unique fingerprint.

Cite this